Skip to content

D&A at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$661K+13.6%
Amgen logo
AmgenAMGN

Segments

By segment

See full
Biopharma$348M+5.1%

Other financials

Income statement

See full
Revenue$14.5B+5.4%
Gross profit$10.9B+0.3%
Net income$2.7B-9.4%
EPS (diluted)$0.47-9.6%

Balance sheet

See full
Cash & equivalents$1.8B+18.8%
Total debt$64.4B+4.9%
Total equity$90.1B-0.3%
Total assets$207.62B-0.2%

Cash flow

See full
Operating cash flow$2.6B+12.0%
CapEx$436.0M-22.7%
Free cash flow$2.2B+23.0%

Valuation

See full
Market cap$138.21B-3.7%
Enterprise value$200.88B-1.3%
P/E11.4×
P/S2.2×-0.1×

Profitability

See full
Gross margin73.5%+1.2pp
Net margin15.7%
FCF margin18%+8.8pp

Returns & leverage

See full
Return on equity10.6%
Debt / equity0.7×0.0×
Current ratio1.2×0.0×

Where this comes from

Reported directly by Pfizer in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pfizer's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pfizer's D&A?
Pfizer (PFE) reported D&A of $1.61B in Q1 2026.
How has Pfizer's D&A changed year-over-year?
Pfizer's D&A increased by 33.2% year-over-year, from $1.21B to $1.61B.
What is the long-term trend for Pfizer's D&A?
Over 4 years (2021 to 2025), Pfizer's D&A has grown at a 6.0% compound annual growth rate (CAGR), from $3.86B to $4.88B.
What does D&A mean?
Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.